English
往期目录
新闻公告
More
化学进展 2013, Vol. 25 Issue (09): 1583-1587 DOI: 10.7536/PC130715 前一篇   后一篇

• 癌症化学预防专辑 •

疫苗与癌症预防

王少明, 乔友林*   

  1. 北京协和医学院 中国医学科学院肿瘤医院 北京100021
  • 收稿日期:2012-12-12 修回日期:2013-07-01 出版日期:2013-09-25 发布日期:2013-07-31
  • 通讯作者: 乔友林 E-mail:qiaoy@cicams.ac.cn
Richhtml ( 3 ) 下载PDF ( 1678 ) 引用
导出 被引次数 ( 7 | 1 )

Vaccine and Cancer Prevention

Wang Shaoming, Qiao Youlin*   

  1. Cancer Institute & Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
  • Received:2012-12-12 Revised:2013-07-01 Online:2013-09-25 Published:2013-07-31

中国人群肿瘤死亡的29.7% 由慢性感染引起,其中肝炎病毒(HBV)、幽门螺杆菌(HP)和人乳头瘤病毒(HPV)是最常见的感染致癌因子。目前已研发成功HBV 预防性疫苗、HP 预防性疫苗和HPV 预防性疫苗,可有效预防上述感染因子引起的肝癌、胃癌和宫颈癌。2012 年5 月颁布的《中国慢性病防治工作规划(2012—2015 年)》明确指出:我国在开发癌症高发地区重点癌症筛查适宜技术的同时,应结合国家免疫规划政策,加强对癌症高风险人群乙型肝炎、人乳头瘤病毒等疫苗的预防接种。因此,本文简要介绍上述三种癌症疫苗的最新研究进展,以期借鉴HBV 疫苗在中国的推广历程和免疫成果,进一步推进和完善我国HBV 疫苗的接种,加速HPV 疫苗和HP 疫苗的引入推广,让肿瘤一级预防的科研成果尽早惠及于民。

关键词： 乙肝病毒疫苗, 人乳头瘤病毒疫苗, 幽门螺杆菌疫苗, 癌症预防

Chronic infection attributes to 29.7% of cancer mortality in China, among which Helicobacter Pylori (HP), Hepatitis B virus (HBV), and Human papillomavirus (HPV) are the three major infectious agents. HBV vaccine and HPV vaccine were respectively developed in 1981 and 2006, and have been proven could efficiently prevent HBV-related hepatocarcinoma and HPV-related cervical cancer. In May of 2012, "China Chronic Disease Prevention and Control Work Plan (2012—2015)" was promulgated. This work plan not only requires exploring appropriate screening technologies for major cancers in high-risk areas, and also requests strengthening the implementation of HBV vaccination and HPV vaccination among high-risk population. Moreover, China announced to have successfully developed HP vaccine recently, which could efficiently prevent HP-related gastric cancer. By summarizing the current research progress of the three anti-cancer prophylactic vaccines, this review made a brief introduction of the great breakthroughs in cancer primary prevention. Furthermore, it also reviewed the implementation history of HBV vaccine in China, and the current gap existing between developed countries and China for HPV vaccine. This review hopes to help Chinese policy makers further improve and complete the HBV vaccination program, to accelerate the launch of HPV vaccination program with the least delay, and to introduce the HP vaccine at appropriate time in China.

Contents
1 Introduction
2 Hepatitis B virus (HBV) vaccine
3 Human papillomavirus (HPV) vaccine
4 Helicobactor Pylori (HP) vaccine
5 Perspective

Key words: Hepatitis B virus (HBV) vaccine, Human papillomavirus (HPV) vaccine, Helicobactor Pylori (HP) vaccine, cancer prevention

中图分类号: 

()

[1] 乔友林 (Qiao Y L). 中华肿瘤杂志(Chinese Journal of Oncology), 2012, 34: 483—485
[2] 夏国良(Xia G L). 中华流行病学杂志(The Chinese Journal of Epidemiology), 2002, 23: 1—3
[3] WHO. World Health Organization. Viral Hepatitis: Report by the Secretariat. 2010 [2012-12-01]. http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_15-en.pdf
[4] Zhou Y H, Wu C, Zhuang H. Chin. Med. J., 2009, 122: 98—102
[5] 朱徐 (Zhu X). 中国计划免疫 (Chin. J. Vac. Immun.), 2000, 6: 193—197
[6] 崔富强(Cui F Q), 甫尔哈提(Pur H T), Stephen Hadler, 梁晓峰 (Liang X F). 中国计划免疫(Chin. J. Vac. Immun.), 2007, 13: 1—3
[7] Liang X F, Bi S L, Yang W Z, et al. Vaccine, 2009, 27: 6550-6557
[8] Colombara D V, Wang S M. Vaccine, 2013, 31(38): 4057—4059. DOI: 10.1016/j.vaccine.2013.06.031
[9] WHO. Biologicals, 2009, 37: 338—344
[10] Garland S M, Hernandez-Avila M, Wheeler C M, et al. N. Engl. J. Med., 2007, 356: 1928—1943
[11] Harper D M. Gynecol. Oncol., 2008, 110: S11—S17
[12] Chen W, Zhang X, Molijn A, et al. Cancer Causes Control, 2009, 20: 1705—1713
[13] Li J, Li L K, Ma J F, et al. Vaccine, 2009, 27: 1210—1215
[14] Zhang S K, Pan X F, Wang S M, et al. Vaccine, 2013, 31: 3244—3249
[15] Zhao F H, Tiggelaar S M, Hu S Y, et al. Asian Pac. J. Cancer Prev., 2012, 13: 2369—2378
[16] Zhao F H, Tiggelaar S M, Hu S Y, et al. Cancer Epidemiol., 2012, 36: 384—390
[17] Kreimer A R, Rodriguez A C, Hildesheim A, et al. J. Natl. Cancer Inst., 2011, 103: 1444—1451
[18] 王少明 (Wang S M), 乔友林 (Qiao Y L). 癌症进展 (Oncology Progress), 2010, 3: 134—138
[19] Canfell K, Shi J F, Lew J B, et al. Vaccine, 2011, 29: 2487—2494
[20] 邹全明 (Zou Q M). 胃肠病学 (Journal of Gastroenterology), 2007, 12: 567—570
[1] 余四旺, 杨中枢. 癌症化学预防在中国——代专辑前言[J]. 化学进展, 2013, 25(09): 1411-1414.
[2] 曾红梅, 陈万青. 中国癌症流行病学与防治研究现状[J]. 化学进展, 2013, 25(09): 1415-1420.
[3] Michael B. Sporn, Karen T. Liby. 癌症化学预防：过去,现在和未来[J]. 化学进展, 2013, 25(09): 1421-1428.
[4] Barbara K. Dunn. 乳腺癌预防的三期临床试验：雌激素靶向药物,选择性雌激素受体调控剂和芳香酶抑制剂[J]. 化学进展, 2013, 25(09): 1429-1449.
[5] Andrew T. Chan. 阿司匹林用于结直肠癌预防[J]. 化学进展, 2013, 25(09): 1450-1453.
[6] 黎钧耀. 癌症的营养干预研究[J]. 化学进展, 2013, 25(09): 1462-1479.
[7] Gary D. Stoner. 癌症预防的完全食物途径：以浆果为例[J]. 化学进展, 2013, 25(09): 1480-1491.
[8] 杨中枢. 维生素E和茶多酚用于癌症预防：动物模型和人群研究的体验[J]. 化学进展, 2013, 25(09): 1492-1500.
[9] Ann M. Bode, 董子钢. 发现癌症化学预防分子靶标的策略[J]. 化学进展, 2013, 25(09): 1501-1516.
[10] 熊东海, Raymond U. Osarogiagbon, 王嫣, 尤明. 驱动基因作为肺癌预防和治疗的靶标[J]. 化学进展, 2013, 25(09): 1517-1525.
[11] 苏正元, 舒利民, Jong Hun Lee, Franciso Fuentes, 王虎, 吴天元, 余四旺, Ah-Ng Tony Kong. 食用植物成分和中药用于癌症化学预防：Nrf2,表观基因组学,癌症干细胞[J]. 化学进展, 2013, 25(09): 1526-1543.
[12] 王秀君*, 李欣, 唐修文. Nrf2通路在肿瘤化学预防中的研究进展[J]. 化学进展, 2013, 25(09): 1544-1552.
[13] 郜嵩, Sumit Basu, 杨广义, Arijita Deb, 胡明. 天然产物用于癌症化学预防的口服生物利用度问题[J]. 化学进展, 2013, 25(09): 1553-1574.
[14] 游伟程*, 张联, 潘凯枫, 马骏岭. 抗幽门螺旋杆菌预防胃癌[J]. 化学进展, 2013, 25(09): 1575-1582.
[15] 陈继冰, 袁远英, 徐克成. 抗肿瘤疫苗的研究进展[J]. 化学进展, 2013, 25(09): 1588-1593.
阅读次数
全文


摘要

疫苗与癌症预防